Abstract Library

#4593 Excellent response to Ac-225 DOTATATE therapy in a patient with small cell lung cancer

Introduction: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for patients with NETs overexpressing somatostatin receptors (SSTR). IHC analysis indicates that up to 50% of small cell lung cancer (SCLC) tumours are SSTR2 positive and thus can be targeted by SSR imaging and PRRT. Therapy with α-emitting radionuclides, such as Ac225, may offer several advantages over β-emitters by having higher energy transfer and more effective cancer cell death.

Conference:

Presenting Author: Tuncel M

Authors: Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S,

Keywords: Ac-225 DOTATATE, Small Cell lung cancer, PET, somatostatin receptor, PRRT,

#4556 Optimising the establishment of patient-derived models for neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are clinically and molecularly diverse, with limited understanding of their tumour biology. Efforts to develop patient-derived models have been unsuccessful, highlighting an urgent need for accurate models to support fundamental research.

Conference:

Presenting Author: Hernández Llorens M

Authors: Hernández-Llorens M, Baena-Moreno M, Lamas-Paz A, Sarmentero J, Anton-Pascual B,

Keywords: patient-derived model, organoids, PDXs, Growth factor,

#4540 Retrospective analysis of somatostatin receptors expression in cohort of thoracic neuroendocrine neoplasms with immunohistochemistry method or PET/CT Ga68 DOTA-TATE

Introduction: Somatostatin receptors (SSTRs) expression in cohort of thoracic neuroendocrine neoplasms (NENs) is still not fully described. We attempted to evaluate the SSTR expression by IHC and PET/CT with Ga68 DOTA-TATE, as well as the sensitivity of both methods.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Vorobeva M, Zhulikov Y, Markovich A, Gorbunova V,

Keywords: NEN, thoracic, SSTR, IHC, DOTATATE, lung, thymus, mediastinum, LCNC, NET,

#4513 Predictive value of different PD-L1 immunohistochemistry clones for immunotherapy efficacy in neuroendocrine tumours: A case series

Introduction: In the ZS001 clinical trial, we observed that NET patients with higher PD-L1 expression levels were more likely to benefit preferentially from immunotherapy.

Conference:

Presenting Author:

Authors: Sun Y, Zhang Q, Cao F, Huang X, Zhang P,

Keywords: neuroendocrine tumour, immunotherapy, PD-L1, SP142, 28-8, C0148, E1L3N,

#4509 Epidemiological characteristics and prognosis analysis of gastric cancer (GC) with neuroendocrine differentiation (NED)

Introduction: GC with NED exhibits distinct biological characteristics, yet research on its clinical features and prognosis remains limited.

Conference:

Presenting Author: Zhang J

Authors: Huang Z, Li J, Wang C, Shen Y, Rao S,

Keywords: gastric cancer, neuroendocrine differentiation, Epidemiological characteristics, prognosis,